SEC Form 4 · accession 0001209191-18-047481
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kalevi Kurkijarvi
Director
Period of report
Aug 16, 2018
Accepted (ET)
Aug 17, 2018 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 16, 2018 | M | 4,000 | $2.90 | A | 27,700 | D | |
| Common StockF2 | Aug 16, 2018 | S | 1,550 | $59.70 | D | 26,150 | D | |
| Common StockF3 | Aug 16, 2018 | S | 2,450 | $60.65 | D | 23,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.90 | Aug 16, 2018 | M | 4,000 | D | — | Jun 24, 2020 | Common Stock | 4,000 | 4,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $59.25 to $60.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $60.25 to $61.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.